Latest filings (excl ownership)
15-12B
Securities registration termination
27 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
POSASR
Automatic shelf registration (post-effective amendment)
24 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 20
8-K
Termination of a Material Definitive Agreement
17 Nov 20
SC 14D9/A
Tender offer solicitation (amended)
17 Nov 20
25-NSE
Exchange delisting
17 Nov 20
SC TO-T/A
Third party tender offer statement (amended)
17 Nov 20
10-Q
2020 Q3
Quarterly report
5 Nov 20
SC 14D9/A
Tender offer solicitation (amended)
5 Nov 20
8-K
MyoKardia Reports Third Quarter 2020 Financial Results
5 Nov 20
SC 14D9/A
Tender offer solicitation (amended)
4 Nov 20
SC TO-T/A
Third party tender offer statement (amended)
4 Nov 20
SC TO-T/A
Third party tender offer statement (amended)
30 Oct 20
SC 14D9/A
Tender offer solicitation (amended)
28 Oct 20
SC 14D9
Tender offer solicitation
19 Oct 20
SC TO-T
Third party tender offer statement
19 Oct 20
SC TO-C
Information about tender offer
6 Oct 20
SC TO-C
Information about tender offer
5 Oct 20
SC14D9C
Written communication relating to third party tender offer
5 Oct 20
SC14D9C
Written communication relating to third party tender offer
5 Oct 20
8-K
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
5 Oct 20
10-Q
2020 Q2
Quarterly report
4 Aug 20
8-K
MyoKardia Reports Second Quarter 2020 Financial Results
4 Aug 20
8-K
Submission of Matters to a Vote of Security Holders
24 Jun 20
8-K
MyoKardia Announces Proposed Public Offering of Common Stock
14 May 20
424B5
Prospectus supplement for primary offering
14 May 20
424B5
Prospectus supplement for primary offering
11 May 20
8-K
Highly Statistically Significant Improvements in NYHA Classification, Peak VO2, and LVOT Gradient Observed vs. Placebo
11 May 20
10-Q
2020 Q1
Quarterly report
6 May 20
8-K
MyoKardia Reports First Quarter 2020 Financial Results
6 May 20
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEF 14A
Definitive proxy
24 Apr 20
8-K
MAVERICK-HCM Phase 2 Clinical Trial Results Consistent with Tolerability Observations from Prior Studies of Mavacamten
30 Mar 20
8-K
MyoKardia Provides Clinical Trial Update in the Context of the COVID-19 Pandemic
26 Mar 20
S-8
Registration of securities for employees
27 Feb 20
Latest ownership filings
SC 13G
INTEGRATED CORE STRATEGIES (US) LLC
27 Nov 20
4
David P Meeker
19 Nov 20
4
Robert Scott McDowell
19 Nov 20
4
Taylor C. Harris
19 Nov 20
4
SUNIL AGARWAL
19 Nov 20
4
William Fairey
19 Nov 20
4
Jake Bauer
19 Nov 20
4
MARK L PERRY
19 Nov 20
4
Kimberly J Popovits
19 Nov 20
4
MARY B CRANSTON
19 Nov 20
4
ANASTASIOS GIANAKAKOS
19 Nov 20
4
WENDY L YARNO
19 Nov 20
4
Denelle J Waynick
19 Nov 20
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
10 Nov 20
SC 13G/A
FMR LLC
10 Nov 20
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
10 Nov 20
4/A
MARY B CRANSTON
30 Oct 20
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
10 Sep 20
4
ANASTASIOS GIANAKAKOS
7 Jul 20
4
Denelle J Waynick
2 Jul 20
3
Denelle J Waynick
2 Jul 20
4
MARY B CRANSTON
1 Jul 20
4/A
MARY B CRANSTON
23 Jun 20
4/A
Kimberly J Popovits
23 Jun 20
4/A
WENDY L YARNO
23 Jun 20
4/A
MARK L PERRY
23 Jun 20
4/A
David P Meeker
23 Jun 20
4/A
SUNIL AGARWAL
23 Jun 20
4
MARK L PERRY
22 Jun 20
4
MARY B CRANSTON
22 Jun 20
4
SUNIL AGARWAL
22 Jun 20
4
Kimberly J Popovits
22 Jun 20
4
David P Meeker
22 Jun 20
4
WENDY L YARNO
22 Jun 20
4
SUNIL AGARWAL
16 Jun 20
4
Kimberly J Popovits
16 Jun 20
4
David P Meeker
16 Jun 20
4
MARK L PERRY
16 Jun 20
4
WENDY L YARNO
16 Jun 20
4
MARY B CRANSTON
16 Jun 20